Alto Neuroscience is a clinical stage biopharmaceutical company. Co.'s Precision Psychiatry Platform, which applies data science and analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices to discover brain-based biomarkers to identify which patients are more likely to respond to its novel product candidates. Co.'s pipeline consists of five clinical-stage assets targeting depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. The ANRO average annual return since 2024 is shown above.
The Average Annual Return on the ANRO average annual return since 2024 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ANRO average annual return since 2024 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ANRO average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|